These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
458 related articles for article (PubMed ID: 24024153)
41. Cystic fibrosis transmembrane conductance regulator (CFTR): Making an ion channel out of an active transporter structure. Linsdell P Channels (Austin); 2018; 12(1):284-290. PubMed ID: 30152709 [TBL] [Abstract][Full Text] [Related]
47. A novel natural product compound enhances cAMP-regulated chloride conductance of cells expressing CFTR[delta]F508. deCarvalho AC; Ndi CP; Tsopmo A; Tane P; Ayafor J; Connolly JD; Teem JL Mol Med; 2002 Feb; 8(2):75-87. PubMed ID: 12080183 [TBL] [Abstract][Full Text] [Related]
48. Understanding how cystic fibrosis mutations cause a loss of Cl- channel function. Sheppard DN; Ostedgaard LS Mol Med Today; 1996 Jul; 2(7):290-7. PubMed ID: 8796909 [TBL] [Abstract][Full Text] [Related]
49. Cystic Fibrosis: Pathophysiology of Lung Disease. Bergeron C; Cantin AM Semin Respir Crit Care Med; 2019 Dec; 40(6):715-726. PubMed ID: 31659725 [TBL] [Abstract][Full Text] [Related]
50. Modeling Cystic Fibrosis Using Pluripotent Stem Cell-Derived Human Pancreatic Ductal Epithelial Cells. Simsek S; Zhou T; Robinson CL; Tsai SY; Crespo M; Amin S; Lin X; Hon J; Evans T; Chen S Stem Cells Transl Med; 2016 May; 5(5):572-9. PubMed ID: 27034411 [TBL] [Abstract][Full Text] [Related]
51. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Mickle JE; Cutting GR Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548 [TBL] [Abstract][Full Text] [Related]
55. Annexin V is directly involved in cystic fibrosis transmembrane conductance regulator's chloride channel function. Trouvé P; Le Drévo MA; Kerbiriou M; Friocourt G; Fichou Y; Gillet D; Férec C Biochim Biophys Acta; 2007 Oct; 1772(10):1121-33. PubMed ID: 17869070 [TBL] [Abstract][Full Text] [Related]
56. Cytoskeleton and CFTR. Edelman A Int J Biochem Cell Biol; 2014 Jul; 52():68-72. PubMed ID: 24685681 [TBL] [Abstract][Full Text] [Related]
57. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis. Jiang Q; Engelhardt JF Eur J Hum Genet; 1998 Jan; 6(1):12-31. PubMed ID: 9781011 [TBL] [Abstract][Full Text] [Related]
58. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis. Yeh JT; Yu YC; Hwang TC J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177 [TBL] [Abstract][Full Text] [Related]
59. Functional characterization of a novel CFTR mutation P67S identified in a patient with atypical cystic fibrosis. Kraus C; Reis A; Naehrlich L; Dötsch J; Korbmacher C; Rauh R Cell Physiol Biochem; 2007; 19(5-6):239-48. PubMed ID: 17495464 [TBL] [Abstract][Full Text] [Related]
60. Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas. Zhang W; Fujii N; Naren AP Future Med Chem; 2012 Mar; 4(3):329-45. PubMed ID: 22393940 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]